Geremia B Bolli

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 27

Top Topics

Community Dwelling

Glycemic Control

Top Venues

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

Acta diabetologica

This page only lists publications with an associated author ORCID identifier.

Publications

Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial. Diabetes, obesity & metabolism (2023)
Geremia B Bolli, Alice Y Y Cheng, David R Owens
Insulin: evolution of insulin formulations and their application in clinical practice over 100 years. Acta diabetologica 59 (9) (2022)
Ivana Rabbone, Erica Pozzi, Silvia Savastio, Galimberti Luca, Morotti Elisa, Frontino Giulio, Geremia B Bolli, Riccardo Bonfanti
A comparison of the effectiveness and safety of insulin glargine 300 U/ml versus 100 U/ml in children and adolescents with newly diagnosed type 1 diabetes: A retrospective, observational, short-term study. Diabetes, obesity & metabolism 24 (12) (2022)
Ernesto Maddaloni, Geremia B Bolli, Brian M Frier, Randie R Little, Richard D Leslie, Pozzilli Paolo, Raffaella Buzzetti
C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective. Diabetes, obesity & metabolism 24 (10) (2022)
Raffaella Buzzetti, Riccardo C Bonadonna, Andrea Giaccari, Gianluca Perseghin, Domenico Cucinotta, Carmine Giuseppe Fanelli, Angelo Avogaro, Gianluca Aimaretti, Monica Larosa, Ilaria Pacchetti, Geremia B Bolli
Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis. Diabetes, obesity & metabolism (2021)
Geremia B Bolli, Francesca Porcellati, Paola Lucidi, Carmine G Fanelli
Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136. Diabetes care 44 (3) (2021)
Geremia B Bolli, Francesca Porcellati, Juris J Meier
Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin. Diabetes care 43 (10) (2021)
Geremia B Bolli, Alice Cheng, Bernard Charbonnel, Vanita R Aroda, Jukka Westerbacka, Zsolt Bosnyak, Emmanuelle Boëlle-Le Corfec, Julio Rosenstock
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial. Diabetes, obesity & metabolism 23 (7) (2021)
David R Owens, Louis Monnier, Antonio Ceriello, Geremia B Bolli
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922. Diabetes, obesity & metabolism (2021)
Thomas Danne, Munehide Matsuhisa, Christian Sussebach, Harmonie Goyeau, Felipe Lauand, Elisabeth Niemoeller, Geremia B Bolli
Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta-analysis of 6-month phase 3 clinical trials. Diabetes, obesity & metabolism 22 (10) (2020)
Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Chiara Pascucci, Angela Gambelunghe, Geremia B Bolli, Carmine Giuseppe Fanelli, Francesca Porcellati
Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL-1 and Insulin Degludec 100 units · mL-1 in Type 1 Diabetes. Diabetes care 44 (1) (2020)
Geremia B Bolli, Wolfgang Landgraf, Zsolt Bosnyak, Lydie Melas-Melt, Philip D Home
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial. Diabetes, obesity & metabolism 22 (9) (2020)
Martin Haluzík, Alice Cheng, Dirk Müller-Wieland, Jukka Westerbacka, Zsolt Bosnyak, Felipe Lauand, Lydie Melas-Melt, Janaka Karalliedde, Julio Rosenstock, Geremia B Bolli
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. Diabetes, obesity & metabolism 22 (8) (2020)
David R Owens, Geremia B Bolli
The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes, obesity & metabolism 22 (5) (2020)
Ulrich Werner, Norbert Tennagels, Carmine Giuseppe Fanelli, Geremia B Bolli
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs. Diabetes, obesity & metabolism 23 (1) (2020)
David R Owens, Wolfgang Landgraf, Brian M Frier, Mei Zhang, Philip D Home, Stephen H Mandy, Geremia B Bolli
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0. Diabetes, obesity & metabolism 21 (2) (2019)
Wolfgang Landgraf, David R Owens, Brian M Frier, Mei Zhang, Geremia B Bolli
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Diabetes, obesity & metabolism 22 (3) (2019)
Yasuo Terauchi, Matthew C Riddle, Takahisa Hirose, Masayoshi Koyama, Xi Cheng, Yoshinori Takahashi, Geremia B Bolli
Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use. Diabetes, obesity & metabolism 20 (11) (2018)
Geremia B Bolli, Carol Wysham, Miles Fisher, Soazig Chevalier, Anna M G Cali, Bruno Leroy, Matthew C Riddle
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. Diabetes, obesity & metabolism 21 (2) (2018)
Robert A Ritzel, Stewart B Harris, Helen Baron, Hermes Florez, Ronan Roussel, Melanie Espinasse, Isabel Muehlen-Bartmer, Nianxian Zhang, Monica Bertolini, Claire Brulle-Wohlhueter, Medha Munshi, Geremia B Bolli
A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. Diabetes care 41 (8) (2018)
Julio Rosenstock, Alice Cheng, Robert A Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías, Ronan Roussel, Geremia B Bolli
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes care 41 (10) (2018)
Brian M Frier, Wolfgang Landgraf, Mei Zhang, Geremia B Bolli, David R Owens
Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus. Diabetes, obesity & metabolism 20 (12) (2018)
Francesca Porcellati, Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Gianluca Curti, Geremia B Bolli, Carmine G Fanelli
Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes. Diabetes care 42 (1) (2018)